scholarly journals Nilotinib early switch efficacy in non-optimal responder CML patient after first line imatinib treatment

2015 ◽  
Vol 5 (6S) ◽  
pp. 11-16
Author(s):  
Ferdinando Porretto
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Mutational Analysis ◽  
Chronic Phase ◽  
Cytogenetic Response ◽  
Imatinib Treatment ◽  
First Line ◽  
Complete Cytogenetic Response ◽  
First Line Therapy ◽  
Line Therapy

We report a case of a patient with chronic myeloid leukemia in chronic phase who was treated with Imatinib as first line therapy. He showed a suboptimal response by 2006 ELN criteria after six months, for this reason we performed a mutational analysis that showed the mutation F486S. Due to this finding we made an early switch to Nilotinib (Nil); patients started Nil at 300 bid mg/day obtaining at six month a complete cytogenetic response (CCyR) and a MMolR (RQ-PCR ratio BCR-ABL1/ABL1%IS: 0.05). The patient is now on 24 months Nil treatment showing a RQ-PCR ratio BCR-ABL1/ABL1%IS: 0.004.

scholarly journals Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

Blood ◽  
2012 ◽  
Vol 120 (2) ◽  
pp. 291-294 ◽  
Author(s):  
David Marin ◽  
Corinne Hedgley ◽  
Richard E. Clark ◽  
Jane Apperley ◽  
Letizia Foroni ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Transcript Level ◽  
Cytogenetic Response ◽  
Molecular Response ◽  
First Line ◽  
Complete Cytogenetic Response ◽  
First Line Therapy ◽  
Line Therapy

Abstract Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complete cytogenetic response (58.8% vs 96.6%, P < .001) and molecular responses than the remaining patients with a lower transcript levels. The predictive value of the 3-month transcript level could be improved using the dasatinib-specific transcript level cut-offs, namely, 2.2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693.

scholarly journals Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

2017 ◽  
Vol 143 (7) ◽  
pp. 1225-1233 ◽  
Author(s):  
Andreas Hochhaus ◽  
Franҫois-Xavier Mahon ◽  
Philipp le Coutre ◽  
Ljubomir Petrov ◽  
Jeroen J. W. M. Janssen ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Deep and early molecular response induced by nilotinb in a newly diagnosed patient with chronic myeloid leukemia (CML)

2015 ◽  
Vol 7 (1S) ◽  
pp. 19-23
Author(s):  
Antonella Russo Rossi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Transcript Level ◽  
Cytogenetic Response ◽  
Molecular Response ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Complete Hematologic Response ◽  
Level Reduction

We report a case of a patient with chronic myeloid leukemia diagnosed in January 2012 and treated with nilotinib 600 mg/die as first line therapy. Patient obtained a complete hematologic response (CHR) and improvement of splenomegaly in 2 weeks. In three months the patient obtained complete cytogenetic response (CCR) and an important transcript level reduction (less than 1%). According to the international recommendations, molecular analysis was performed every three months in a LABNET network laboratory. Treatment was never interrupted or reduced due to any adverse event. After 9 months patient achieved a major molecular response (MMR) and during evaluation a MR4 has been documented.

A Decade Of Imatinib As First-Line Treatment Of Chronic Myeloid Leukemia: A Single - Latin American Institution Experience

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5194-5194
Author(s):  
Alvaro Cabrera Garcia ◽  
Carolina Balderas Delgado ◽  
Juan Julio Kassack Ipiña ◽  
Christian Omar Ramos Peñafiel ◽  
Juan Collazo Jaloma ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Latin American ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Hematologic Toxicity ◽  
Line Treatment ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Eutos Score

Abstract Targeted therapy commenced against Chronic Myeloid Leukemia (CML) with the development of small-molecule tyrosine kinase inhibitors (TKIs), since its approval in 2001 as first-line therapy, imatinib has been effective in achieving high response rates and improving the prognosis. However, the excellent results of large clinical trials are not entirely reproducible in the “real world”, we want to share our experience of a decade of use as front-line treatment. A total of 160 patients with previously untreated CML since 2002 were reviewed: 90% chronic phase (CP), 7% accelerated phase (AP), and 3% blast phase (BP). All were treated with standard-dose imatinib. In CP, overall survival (OS) at 75 months was 82% and progression-free survival 66%(PFS). Survival was worse in those over 60 years (P= < .001). 40% achieved and maintained Complete Cytogenetic Response (CCyR), 19 patients progressed to BP. 23.4% had some degree of hematologic toxicity that required a temporary suspension or reduction of the initial dose. 26.8% of patients with chronic phase treated at our institution were in the high EUTOS score. In this population, the EUTOS score was not predictive for outcome. Our study showed that imatinib is effective, and well tolerated by our patients and remains as a good strategy used as first-line therapy for patients with CML. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Efficacy and safety of Bosutinib in Patient with Chronic myeloid leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report

2021 ◽  
Author(s):  
Abdullah Mohammad Arshad ◽  
mohamed yassin
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Molecular Response ◽  
Efficacy And Safety ◽  
Major Molecular Response ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Bosutinib is approved as first line therapy for treatment of chronic phase CML and also in patients who are either resistant or intolerant to previous TKI. We present a 59 year old male who was intolerant to 2 TKI but showed excellent hematological and major molecular response to Bosutinib.

Sign in / Sign up

Export Citation Format

Share Document